ranolazine has been researched along with Cardiac Conduction Defect in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Beserra, SS; Campos, DR; Miranda, VM | 1 |
| Abdelsayed, M; Ruben, PC; Ruprai, M | 1 |
| van den Berg, MP; van den Heuvel, F; van Gelder, IC; van Tintelen, JP; Volders, PG | 1 |
| Belardinelli, L; Kanas, AF; Morrow, DA; Nearing, BD; Nieminen, T; Pagotto, VP; Pegler, JR; Scirica, BM; Sobrado, MF; Tavares, C; Umez-Eronini, AA; Verrier, RL | 1 |
| Chao, TF; Chen, SA; Chen, YC; Chen, YJ; Chung, FP; Huang, JH; Kao, YH; Lu, YY; Tsai, CF | 1 |
| Belardinelli, L; Bhimani, AA; Khrestian, CM; Lee, S; Sadrpour, SA; Waldo, AL; Yasuda, T; Zeng, D | 1 |
| Chen, SA; Chen, YC; Chen, YJ; Cheng, CC; Lu, YY | 1 |
1 trial(s) available for ranolazine and Cardiac Conduction Defect
| Article | Year |
|---|---|
Relation of T-wave alternans to mortality and nonsustained ventricular tachycardia in patients with non-ST-segment elevation acute coronary syndrome from the MERLIN-TIMI 36 trial of ranolazine versus placebo.
Topics: Acetanilides; Acute Coronary Syndrome; Aged; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Death, Sudden, Cardiac; Electrocardiography; Enzyme Inhibitors; Female; Heart Conduction System; Humans; Male; Middle Aged; Piperazines; Placebos; Predictive Value of Tests; Ranolazine; Risk Factors; Tachycardia, Ventricular; Treatment Outcome | 2014 |
6 other study(ies) available for ranolazine and Cardiac Conduction Defect
| Article | Year |
|---|---|
Inotropic and Antiarrhythmic Transmural Actions of Ranolazine in a Cellular Model of Type 3 Long QT Syndrome.
Topics: Action Potentials; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Conduction System Disease; Humans; Long QT Syndrome; Ranolazine | 2020 |
The efficacy of Ranolazine on E1784K is altered by temperature and calcium.
Topics: Action Potentials; Brugada Syndrome; Calcium; Cardiac Conduction System Disease; HEK293 Cells; Humans; Long QT Syndrome; Mutation; NAV1.5 Voltage-Gated Sodium Channel; Ranolazine; Sodium; Temperature | 2018 |
Successful treatment of a patient with symptomatic long QT syndrome type 3 using ranolazine combined with a beta-blocker.
Topics: Acetanilides; Adrenergic beta-Antagonists; Adult; Cardiac Conduction System Disease; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Humans; Long QT Syndrome; Piperazines; Ranolazine; Sodium Channel Blockers; Treatment Outcome | 2014 |
Distinctive electrophysiological characteristics of right ventricular out-flow tract cardiomyocytes.
Topics: Acetanilides; Action Potentials; Animals; Arrhythmias, Cardiac; Benzylamines; Brugada Syndrome; Calcium; Cardiac Conduction System Disease; Electrophysiological Phenomena; Enzyme Inhibitors; Heart Conduction System; Heart Ventricles; Myocytes, Cardiac; Patch-Clamp Techniques; Piperazines; Protein Kinase Inhibitors; Rabbits; Ranolazine; Sodium-Calcium Exchanger; Sulfonamides | 2014 |
Ranolazine terminates atrial flutter and fibrillation in a canine model.
Topics: Acetanilides; Animals; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Brugada Syndrome; Cardiac Conduction System Disease; Disease Models, Animal; Dogs; Electrocardiography; Enzyme Inhibitors; Heart Conduction System; Heart Rate; Injections, Intravenous; Piperazines; Ranolazine; Sodium Channel Blockers; Treatment Outcome | 2014 |
ATX-II-induced pulmonary vein arrhythmogenesis related to atrial fibrillation and long QT syndrome.
Topics: Acetanilides; Action Potentials; Analysis of Variance; Animals; Atrial Fibrillation; Cardiac Conduction System Disease; Cardiotonic Agents; Cnidarian Venoms; Dose-Response Relationship, Drug; Enzyme Inhibitors; Heart Atria; Humans; Long QT Syndrome; Models, Animal; Piperazines; Pulmonary Veins; Rabbits; Ranolazine | 2012 |